Detection of Dermo in oysters in Prince Edward Island
To limit the spread of the disease, the CFIA, Fisheries and Oceans Canada (DFO) and the Province of PEI are working together with partners to monitor the situation and take necessary action. These actions are part of the Government of Canada's One Health approach to prepare for, detect, and manage animal diseases.
In addition to existing robust protective measures and increased animal surveillance, the CFIA, DFO and the Province of PEI continue to conduct activities to gain insight into the presence of Dermo in the area. At this time, these response measures include:
Quick Facts
Related links
Follow us on social media
Facebook: CFIACanada
X: @InspectionCan
YouTube: @CFIA
Instagram: @CFIA_Canada
LinkedIn: Canadian Food Inspection Agency
Each day, hard-working Canadian Food Inspection Agency employees—including inspectors, veterinarians, and scientists—inspect food for safety risks, work to protect plants from pests and invasive species, and respond to animal diseases that could threaten Canada's animal resource base and human health. Guided by science-based decision-making and modern regulations, the Agency verifies that food sold in Canada is safe while supporting access to international markets for our high-quality agricultural products. To learn more, visit inspection.canada.ca
SOURCE Canadian Food Inspection Agency (CFIA)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
37 minutes ago
- Associated Press
Aires Hosts Two First-Ever Events: Demo Day Symposium at UFC's Performance Institute & Roundtable on Environmental Wellness
Toronto, Ontario--(Newsfile Corp. - July 7, 2025) - American Aires Inc. (CSE: WIFI) (OTCQB: AAIRF) ('Aires' or the 'Company'), a pioneer in advanced technology designed to optimize electromagnetic field (EMF) environments to support health and well-being, hosted two first-ever events in Las Vegas, Nevada, on June 25 and 26, 2025 (see event details below). Both events focused on how people can take an active role in designing and controlling their environment as a new pillar of wellness and health optimization. As part of the events, Aires premiered a video demonstrating the Company's performance-enhancing technology through data from brain scans and heart rate variability (HRV) when exposed to electromagnetic environments with and without the presence of Aires' environmental tuning products. The video can be viewed here: The Aires marketing team captured the exclusive conversations and interactions at both events, which will be repurposed as digital assets to support the Company's educational, brand awareness, and sales campaigns. [ This video cannot be displayed. Please visit the source: ] Cannot view this video? Visit: Aires CEO, Josh Bruni, commented: 'For the first time, the conversation around health at UFC's International Fight Week included the invisible biological input that influences strength, stamina and recovery: our electromagnetic environment. Most people aren't aware that their electromagnetic environment — internal and external — is continually shaping their biology. They've also never seen scientific data showing how that environment can be proactively and precisely tuned to improve biological outcomes and performance. That's why we initiated and hosted these events. They're the latest example of Aires' commitment to educating people about how the invisible electromagnetic environment is a core pillar of health, just like other universally accepted biological factors such as water, sleep, movement, and nutrition. The importance of that message was reinforced by the enthusiastic participation of the world-class experts, specialists and peak performers that contributed and shared their knowledge. Our commitment is to continue making the invisible visible through events like these and through our marketing efforts so that more people, organizations and businesses learn how Aires can help transform the electromagnetic environments around us all to promote well-being.' Event #1: Demo Day Symposium at UFC's Performance Institute The Demo Day Symposium was held at the UFC's Performance Institute (PI) during UFC's International Fight Week on Wednesday, June 25. The symposium's focus on the biological impacts of electromagnetic environments aligned with UFC PI's dedication to peak performance, recovery, and human potential. The event included a panel discussion with Aires CEO Josh Bruni, the PI's Vice President of Performance Dr. Duncan French, neuroscientist Dr. Dogris, and top athletes. Event #2: Built For Brilliance Roundtable on Environmental Wellness On Thursday, June 26, Aires hosted the Roundtable on Environmental Wellness in partnership with Biohack Yourself Media ( ). The event explored the influence of environment — including electromagnetic environments and electromagnetic fields (EMFs) — on sleep, stress, physical recovery and cognition. The roundtable's conversation was hosted by Biohack Yourself Media's TereZa Lolli, and brought together leaders from the fields of peak performance, medicine, and environmental design, including: About American Aires Inc. American Aires Inc. is a Canadian-based nanotechnology company committed to enhancing well-being and environmental safety through science-led innovation, education, and advocacy. The company is selling a line of proprietary patented silicon-based resonator products that optimize electromagnetic field (EMF) environments to support health and well-being.* Aires' Lifetune products diffract EMF radiation emitted by consumer electronic devices such as cellphones, computers, baby monitors, and Wi-Fi, including the more powerful and rapidly expanding high-speed 5G networks. The Aires Certified Spaces TM ( ) standard is a set of protocols for implementing EMF modulation solutions to create authorized EMF-friendly spaces that support well-being in a tech-driven world. Aires is listed on the CSE under the ticker 'WiFi' and on the OTCQB under the symbol 'AAIRF'. Learn more at and *Note: Based on the Company's internal and peer-reviewed research studies and clinical trials. For more information, please visit On behalf of the board of directors Company Contact: Josh Bruni, CEO Website: Email: [email protected] Telephone: (415) 707-0102 Investor Relations Contact Grant Pasay (415) 707-0102 [email protected] Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. All statements other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding future financial position, future market position, growth, innovations, global impact, business strategy, product adoption, use of proceeds, corporate vision, proposed acquisitions, strategic partnerships, joint ventures and strategic alliances and co-operations, budgets, cost and plans and objectives of or involving the Company. Such forward-looking information reflects management's current beliefs and is based on information currently available to management. Often, but not always, forward-looking statements can be identified by the use of words such as 'plans', 'expects', 'is expected', 'budget', 'scheduled', 'estimates', 'forecasts', 'predicts', 'intends', 'targets', 'aims', 'anticipates' or 'believes' or variations (including negative variations) of such words and phrases or may be identified by statements to the effect that certain actions 'may', 'could', 'should', 'would', 'might' or 'will' be taken, occur or be achieved. A number of known and unknown risks, uncertainties and other factors may cause the actual results or performance to materially differ from any future results or performance expressed or implied by the forward-looking information. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company including, but not limited to, the impact of general economic conditions, industry conditions and dependence upon regulatory approvals. Certain material assumptions regarding such forward-looking statements may be discussed in this news release and the Company's annual and quarterly management's discussion and analysis filed at Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by securities laws. No securities regulatory authority has either approved or disapproved of the contents of this news release. The Shares have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States, or to or for the account or benefit of any person in the United States, absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any common shares in the United States, or in any other jurisdiction in which such offer, solicitation or sale would be unlawful. We seek safe view the source version of this press release, please visit
Associated Press
an hour ago
- Associated Press
BioNxt's Sublingual Cladribine Program for MS Ready for Next Phase
VANCOUVER, BC / ACCESS Newswire / July 7, 2025 / BioNxt Solutions Inc. ('BioNxt' or the 'Company') (CSE:BNXT)(OTC:XPHYF)(FSE:4XT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce the receipt of the active pharmaceutical ingredient (API) for its lead product candidate, BNT23001. This proprietary sublingual thin-film formulation of cladribine is being developed for the treatment of multiple sclerosis (MS). The delivery of the cladribine API enables the commencement of clinical batch manufacturing in collaboration with BioNxt's European contract research and development partner, Gen-Plus GmbH & Co KG, based in Munich, Germany. This milestone supports the company's plan to initiate a human bioequivalence study in the second half of 2025. BNT23001 is designed to offer a patient-friendly alternative to traditional oral cladribine tablets, such as Mavenclad®, by providing a rapidly dissolving sublingual film. This delivery method aims to enhance patient compliance, particularly for individuals with MS who experience dysphagia, a common symptom affecting the ability to swallow. Preclinical studies have demonstrated that BNT23001 achieves high absorption rates and bioequivalence to existing oral therapies, with no adverse toxic effects observed. These findings support the progression to human bioequivalence studies. BioNxt has also made significant strides in securing intellectual property rights for BNT23001. The company has initiated patent nationalization processes in key jurisdictions, including Europe, the United States, and Canada, with patent grants anticipated by mid-2025. 'The receipt of the cladribine API is a pivotal step forward in our mission to develop innovative, patient-centric therapies for MS,' said Hugh Rogers, CEO of BioNxt Solutions. 'We are committed to advancing BNT23001 through clinical development and bringing this novel treatment option to patients worldwide.' About BioNxt Solutions Inc. BioNxt Solutions Inc. is a bioscience innovator focused on next‐generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin‐Film), Transdermal (Skin Patch), and Oral (Enteric‐Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity. With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient‐centric solutions that enhance treatment outcomes worldwide. BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit . Investor Relations & Media Contact Hugh Rogers, Co‐Founder, CEO and Director Email: [email protected] Phone: +1 778.598.2698 Web: LinkedIn: Instagram: Cautionary Statement Regarding 'Forward‐Looking' Information This news release includes certain statements that may be deemed 'forward-looking statements'. All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words 'expects', 'plans', 'anticipates', 'believes', 'intends', 'estimates', 'projects', 'potential' and similar expressions, or that events or conditions 'will', 'would', 'may', 'could' or 'should' occur. Forward-looking information in this news release includes the anticipated filing date of the Annual Filings. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change. SOURCE: BioNxt Solutions Inc. press release
Yahoo
2 hours ago
- Yahoo
Experts urge more awareness of solvent abuse, after explosion in Yellowknife last week
Last week's explosion in downtown Yellowknife has some health and addictions experts urging people to pay attention to the risks associated with inhalants and to consider why people might be abusing those substances. Police said the explosion last week happened as someone was "huffing" propane from a parked boat. The incident left one person in critical condition, and debris from the blast scattered around the neighbourhood. The incident also prompted Yellowknife RCMP and youth organizations to renew calls for city residents to lock up propane. The age of the individual involved in Tuesday's incident was not released but the head of a local youth organization in the N.W.T. said that she's long been concerned about young people using solvents. Seth Fletcher, a Toronto-based addictions counsellor for the Canadian Centre for Addictions says there's reason for concern. He says inhalant and solvent abuse is often associated with underlying mental health issues and pain management. "In a lot of Northern communities, the most easily accessible mind-altering substance that allows a person to self medicate or escape painful emotions, thoughts, feelings, underlying issues are inhalants, propane, chemicals you might find in your kitchen," Fletcher said. He says addressing and treating inhalant abuse starts with having a conversation. "We need to understand the why. Once we understand the why, we can start applying healthier interventions, giving more effective coping mechanisms, helping them nurture those new coping mechanisms until they become the first line of defence," said Fletcher. Fletcher, who has worked in Nunavut, noted that it's sometimes difficult to access help in the North, where there are limited options for timely treatment. Fletcher said that medical monitoring should be a part of any treatment due to the health risks associated with substances. He also says it's equally important to support individuals after treatment. Fletcher says working in Nunavut he saw the effects of inhalant use and it was a heartbreaking part of the job. "Physically, you see damage to the respiratory system — so, people's mouths, their nasal cavities, nerve damage, sometimes the breathing is compromised, just from having those chemicals being inhaled," said Fletcher. Dr. Andre Corriveau, the acting chief public health officer for the N.W.T., says he's also concerned about the dangers of inhalant use. He said different kinds of inhalants have varying effects on a person's organs but a similarity among them is that using them can result in a lack of oxygen in the lungs. "Which then can cause cell death really quickly, within minutes. If it's more prolonged, and propane in particular, it's a heavier gas, and so it can hang around in the lungs for quite some time," said Corriveau. He added that the damage can be permanent, especially to the nervous system, brain, liver, and kidneys, and some substances such as butane, propane and chemicals in aerosols, can cause death. Yellowknife RCMP say they saw nine occurrences last year where inhalant or solvent abuse was identified. So far in 2025, there have also been nine occurrences according to police. Between July 2023 and this week there have been 37 instances documented by Yellowknife RCMP where "huffing" and "sniffing" were included in the summary of occurrences. Police have also recorded several thefts of fuel containers in Yellowknife over the last two years, with four gasoline containers and five propane containers taken in Yellowknife. Following last week's explosion, Yellowknife RCMP have again encouraged residents to lock up any propane or other gases they have on their property. In a news release, RCMP say that in addition to the internal health risks, inhalants are volatile substances that can explode or cause fires "under the right conditions."
